menu

Attention Deficit Hyperactivity Disorder Market

Schedule Call

Attention Deficit Hyperactivity Disorder Market

Attention Deficit Hyperactivity Disorder Market by Drug Class (Stimulant, Non-stimulant), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Outlook and Forecast 2023-2031

GR - 780026 Category: Pharmaceuticals

Number of pages: 100  |  Report Format: PDF  |  Published date: March 21, 2023

Historical Years – 2021  |  Base Year – 2022  |  Forecasted Years – 2023-2031


Attention Deficit Hyperactivity Disorder Market Scope

Report Attribute

Details

Market Size Value in 2022

US$ 13.6 billion

Revenue Forecast in 2031

US$ 20.1 billion

CAGR

4.4%

Base Year for Estimation

2022

Forecast Period

2023-2031

Historical Year

2021

Segments Covered

Drug Class, Distribution Channel, and Region

Regional Scope

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global attention deficit hyperactivity disorder market was valued at US$ 13.6 billion in 2022 and is expected to register a revenue CAGR of 4.4% to reach US$ 20.1 billion by 2031. 

Attention Deficit Hyperactivity Disorder Market Fundamentals 

One of the most prevalent mental illnesses affecting adults and children is attention deficit hyperactivity disorder (ADHD). Inattentiveness, hyperactivity, excessive movement that is inappropriate for the situation, and impulsivity (hasty acts that occur at the moment without thought) are signs of ADHD. The effects of ADHD are known to affect a person in many aspects of their life, including academic and professional success, interpersonal connections, and daily functioning. ADHD is regarded as a chronic and disabling illness. When left untreated, ADHD in kids can result in low self-esteem and poor social skills. Adults with this disease may have low self-esteem, sensitivity to criticism, and increased self-criticism, potentially resulting from receiving more complaints.

About 2.5% of adults and 8.4% of children are thought to have ADHD. In school-aged children, it is frequently initially noticed when it causes disruptions in the classroom or issues with homework. Most of the time, counseling and medication are used to treat ADHD. The suggested first-line approach for preschoolers and younger kids comprises behavioral techniques in parent management training and school intervention. An evidence-based treatment approach for young children with ADHD and oppositional defiant disorder is parent-child interaction therapy. Amphetamines and methylphenidate are the first-line pharmacological therapy for the management of ADHD, according to current recommendations. Amphetamines are the only FDA-approved treatment for ADHD in preschool-aged kids. At the same time, guidelines suggest that methylphenidate may be more effective if behavioral therapies fail to control symptoms. The other FDA-approved medications for treating ADHD are the alpha agonists (clonidine and guanfacine) and the selective norepinephrine reuptake inhibitor, atomoxetine. There are more recent drugs that the FDA has approved for the treatment of ADHD, such as Jornay (methylphenidate extended-release), Xelstrym (dextroamphetamine), an amphetamine patch, Qelbree (viloxazine), a non-stimulant, Adhansia (methylphenidate hydrochloride), Dyanavel (amphetamine extended-release oral suspension), Mydayis (mixed salts amphetamine product), and Cotempla (methylphenidate extended-release orally disintegrating tablets).

[96786]

Attention Deficit Hyperactivity Disorder Market Dynamics

The increasing prevalence of ADHD is expected to spur the global attention deficit hyperactivity disorder market revenue growth. The Attention Deficit Hyperactivity Disorder Institute estimates that the disorder affects between 0.1% and 8.1% of children and adolescents globally. In Asia, Europe, North America, and MEA, the mean prevalence of ADHD in adults between 18 and 45 is almost 2.8%. Also, in most cases, it is considered that the genes acquired from the parents play a key role in developing the disorder because ADHD tends to pass it down through families. According to research, those with ADHD are more likely to have parents or siblings who also have the disease. Studies conducted independently have brought attention to the huge genetic burden on the world. Until recently, several countries lacked newborn screening programs, resulting in a growing percentage of the global population suffering from hereditary illnesses. Therefore, the increasing prevalence of genetic disorders fuels the need for proper treatment, which drives the growth of several genetic diseases, including attention deficit hyperactivity.

One of the major risk factors for developing ADHD in a newborn is premature birth. Prematurity is the number one cause of death for children under five worldwide. Global discrepancies in survival rates are obvious. Half of the newborns in low-income areas are born at or before 32 weeks. Preterm infants who survive the newborn period are suffering from an increasing burden of disability due to the suboptimal use of technology in middle-income settings. According to WHO estimates, in 2022, every year, 15 million babies are born preterm (before 37 completed weeks of gestation). Thus, the increased premature birth rate potentially influences the attention deficit hyperactivity disorder market. 

Due to growing government financing and public awareness of mental health, the market for attention deficit hyperactivity disorder is set to grow. Governments worldwide have been compelled to step in due to the growing number of people experiencing a variety of mental health illnesses, including ADHD. According to the Regional Development Australia updates from July 2021, The New South Wales (NSW) Government has contributed US$ 1.8 million in funding for the ADHD pilot program in 2021–2022, for a total investment of US$ 7.7 million on behalf of the trial of a new model of care and management for kids with behavioral issues, including ADHD in regional NSW.

However, lack of awareness about mental health, including ADHD with poor diagnosis, is the key factor inhibiting the growth of the attention deficit hyperactivity disorder market. Due to the absence of proper knowledge, the diseases remain untreated in kids. Also, in several countries, the market revenue growth is affected due to the unavailability of newborn screening programs. 

Attention Deficit Hyperactivity Disorder Market Ecosystem

The global attention deficit hyperactivity disorder market is analyzed from three perspectives: drug class, distribution channel, and region. 

Attention Deficit Hyperactivity Disorder Market by Drug Class

[96965]

Based on the drug class, the global attention deficit hyperactivity disorder market is segmented into stimulants and non-stimulants. The stimulants segment is sub-segmented into amphetamine, methylphenidate, lisdexamfetamine, dexmethylphenidate, and dextroamphetamine. Also, the non-stimulant segment is sub-segmented into atomoxetine, guanfacine, clonidine, and others. 

The stimulants segment accounted for the largest revenue share of the global attention deficit hyperactivity disorder market in 2022. The most often utilized stimulants for treating ADHD are methylphenidate and amphetamines. These are the first-line medications for ADHD treatment. Methylphenidate is the most frequently used ADHD medication. In the last few years, the usage of stimulants for the treatment of ADHD in college students and children has expanded considerably. Stimulants can help with ADHD symptoms, including attention deficit disorder, impulsive behavior, and restlessness. These medications help 70% of adults and 70%-80% of children with ADHD symptoms. They have been shown to lessen interruptions, fidgeting, and other hyperactive symptoms. They also enhance interactions with family and friends. Stimulants for ADHD improve driving skills and reduces all types of accidents. Also, regular stimulant medication lowers delinquency, substance misuse, crime, and suicidality. Adults can benefit from stimulant medicines as well. It has resulted in a significant increase in the pharmaceutical treatment of people with ADHD.

When stimulants are administered upon waking, delayed action can cause communal problems for many people. Therefore, non-stimulant is frequently used to manage the situation. Atomoxetine, guanfacine XR, and clonidine XR are considered second-line treatments for ADHD. Thus, the advancement in the development of non-stimulant drugs is also increasing significantly to hold the second large revenue share of the global attention deficit hyperactivity disorder market. 

Attention Deficit Hyperactivity Disorder Market by Distribution Channel

Based on the distribution channel, the global attention deficit hyperactivity disorder market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. 

The hospital pharmacies segment accounted for the largest revenue share of the global attention deficit hyperactivity disorder market in 2022. General hospital psychiatry has taken the lead in improving clinical care, training, and research in the last few decades. It has become a significant force in the overall development of mental health. In addition to adapting to the needs of people with mental disorders, general hospital psychiatric services also developed within the constraints imposed by the general hospital organization and culture. As a result, the biomedical method was frequently used. Although there was a strong emphasis on psychological treatment, particularly in the early stages of the general hospital movement, physical therapeutic approaches predominated. By its very nature, the culture of general hospitals supported the creation of classification systems for diseases, physical therapy techniques, and reliance on physicians and nursing staff. The hospital pharmacy is a crucial hospital division that handles the purchase, storage, compounding, dispensing, manufacture, testing, packaging, and distribution of medicines. This department is also in charge of conducting research in pharmaceutical science and education, which is done under the supervision of qualified pharmacists. The hospital pharmacy significantly influences the economics of health costs. The hospital pharmacy nowadays offers both medication monitoring services and drug information services. The hospital pharmacist is competent in drug procurement, handling, pricing, and dispensing. Also, pharmacists serve as a liaison between patients and doctors and offer drug information to the public and all other healthcare professionals.

Attention Deficit Hyperactivity Disorder Market by Region

Based on the region, the global attention deficit hyperactivity disorder market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. 

North America accounted for the largest revenue share of the global attention deficit hyperactivity disorder market in 2022. Due to the introduction and quick adoption of several ADHD medications, North America’s attention deficit hyperactivity disorder market expanded significantly. Furthermore, improved patient affordability, attractive reimbursement policies, and a rise in public awareness of current treatment modalities in North America significantly influence the market revenue. The high prevalence of ADHD in the American population necessitates advanced treatment for ADHD. The Centre for ADHD Awareness Canada stated that almost 1.5 million people in Canada are impacted by ADHD. 

Attention Deficit Hyperactivity Disorder Market Competitive Landscape

Due to new product launches, mergers, and acquisitions, the global attention deficit hyperactivity disorder market is moderately competitive. Some of the primary development strategies that many organizations prioritize include the introduction of novel therapies, securing approval for those goods, and taking part in additional initiatives, including awareness projects. Moreover, the market categorized partnerships, acquisitions, and numerous other forms of collaboration as better growth tactics. With the expanding global market demand for ADHD, these actions have raised the chance of having profitable growth prospects in the future.

Notable market participants include:

Attention Deficit Hyperactivity Disorder Market Strategic Developments

  • In March 2022, Neos Therapeutics reported the United States release of Adzenys XR-ODT, the first orally disintegrating medication for treating ADHD in patients six and older
  • In February 2022, Noven received Food and Drug Administration (FDA) approval for the Xelstrym (dextroamphetamine) transdermal system for treating ADHD for adults and pediatric patients six years and older
  • In April 2021, the FDA approved Qelbree (KELL’-bree) for treating ADHD in children ages 6 to 17
  • In February 2021, Noven Pharmaceuticals Inc. submitted a New Drug Application to the United States FDA seeking approval to market its dextroamphetamine transdermal system for the treatment of ADHD for patients 6 years and older
  • In June 2020, Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc., a subsidiary in the United States, reported positive top-line results from phase 3 clinical trials evaluating the efficacy, safety, and tolerability of oral centanafadine, a novel investigational compound for the treatment of adult patients with ADHD

Frequently Asked Questions About This Report

Attention deficit hyperactivity disorder (ADHD) is a chronic condition with symptoms such as attention difficulty, hyperactivity, and impulsiveness in children and adults.

Increased prevalence of the genetic disorder, mental illness, and strong clinical pipeline for ADHD drugs are the key factors driving the revenue growth of the global attention deficit hyperactivity disorder market.

The lack of awareness and negligence of the symptoms are restraining factors for the revenue growth of the attention deficit hyperactivity disorder market.

Key companies operating the global attention deficit hyperactivity disorder market include Pfizer, Inc., Johnson & Johnson Services, Inc., Lupin Limited, Novartis AG, and Takeda Pharmaceutical Company Limited.

The global attention deficit hyperactivity disorder market is expected to grow at a revenue CAGR of 4.4% during the forecast period from 2023 to 2031.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
  3. PREMIUM INSIGHTS
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022) 
    3. Regulatory Landscape
    4. Reimbursement Scenario 
    5. Epidemiology and Patient Population (Forecast to 2031)
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
  5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET - ANALYSIS & FORECAST, BY DRUG CLASS
    1. Stimulants
      1. Amphetamine
      2. Methylphenidate
      3. Lisdexamfetamine Dimesylate
      4. Dexmethylphenidate
      5. Dextroamphetamine
    2. Non-stimulants
      1. Atomoxetine
      2. Bupropion 
      3. Guanfacine
      4. Clonidine
      5. Others
  6. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET - ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
    1. Hospital Pharmacies
    2. Retail Pharmacies
    3. Online Pharmacies
  7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET - ANALYSIS & FORECAST, BY REGION
    1. North America Attention Deficit Hyperactivity Disorder Market
      1. North America Attention Deficit Hyperactivity Disorder Market, by Drug Class
      2. North America Attention Deficit Hyperactivity Disorder Market, by Distribution Channel
      3. North America Attention Deficit Hyperactivity Disorder Market, by Country
        1. U.S.
          1. U.S. Attention Deficit Hyperactivity Disorder Market, by Drug Class 
          2. U.S. Attention Deficit Hyperactivity Disorder Market, by Distribution Channel
        2. Canada
          1. Canada Attention Deficit Hyperactivity Disorder Market, by Drug Class 
          2. Canada Attention Deficit Hyperactivity Disorder Market, by Distribution Channel
    2. Europe Attention Deficit Hyperactivity Disorder Market
      1. Europe Attention Deficit Hyperactivity Disorder Market, by Drug Class 
      2. Europe Attention Deficit Hyperactivity Disorder Market, by Distribution Channel 
      3. Europe Attention Deficit Hyperactivity Disorder Market, by Country/Region
        1. Germany
          1. Germany Attention Deficit Hyperactivity Disorder Market, by Drug Class 
          2. Germany Attention Deficit Hyperactivity Disorder Market, by Distribution Channel 
        2. U.K.
          1. U.K. Attention Deficit Hyperactivity Disorder Market, by Drug Class 
          2. U.K. Attention Deficit Hyperactivity Disorder Market, by Distribution Channel 
        3. France
          1. France Attention Deficit Hyperactivity Disorder Market, by Drug Class 
          2. France Attention Deficit Hyperactivity Disorder Market, by Distribution Channel
        4. Spain
          1. Spain Attention Deficit Hyperactivity Disorder Market, by Drug Class 
          2. Spain Attention Deficit Hyperactivity Disorder Market, by Distribution Channel 
        5. Italy
          1. Italy Attention Deficit Hyperactivity Disorder Market, by Drug Class 
          2. Italy Attention Deficit Hyperactivity Disorder Market, by Distribution Channel 
        6. Rest of Europe 
          1. Rest of Europe Attention Deficit Hyperactivity Disorder Market, by Drug Class 
          2. Rest of Europe Attention Deficit Hyperactivity Disorder Market, by Distribution Channel 
    3. Asia Pacific Attention Deficit Hyperactivity Disorder Market
      1. Asia Pacific Attention Deficit Hyperactivity Disorder Market, by Drug Class 
      2. Asia Pacific Attention Deficit Hyperactivity Disorder Market, by Distribution Channel 
      3. Asia Pacific Attention Deficit Hyperactivity Disorder Market, by Country/Region
        1. China
          1. China Attention Deficit Hyperactivity Disorder Market, by Drug Class 
          2. China Attention Deficit Hyperactivity Disorder Market, by Distribution Channel 
        2. Japan
          1. Japan Attention Deficit Hyperactivity Disorder Market, by Drug Class 
          2. Japan Attention Deficit Hyperactivity Disorder Market, by Distribution Channel
        3. India
          1. India Attention Deficit Hyperactivity Disorder Market, by Drug Class 
          2. India Attention Deficit Hyperactivity Disorder Market, by Distribution Channel 
        4. South Korea
          1. South Korea Attention Deficit Hyperactivity Disorder Market, by Drug Class 
          2. South Korea Attention Deficit Hyperactivity Disorder Market, by Distribution Channel
        5. Australia
          1. Australia Attention Deficit Hyperactivity Disorder Market, by Drug Class 
          2. Australia Attention Deficit Hyperactivity Disorder Market, by Distribution Channel 
        6. Rest of Asia Pacific
          1. Rest of Asia Pacific Attention Deficit Hyperactivity Disorder Market, by Drug Class 
          2. Rest of Asia Pacific Attention Deficit Hyperactivity Disorder Market, by Distribution Channel 
    4. Latin America Attention Deficit Hyperactivity Disorder Market
      1. Latin America Attention Deficit Hyperactivity Disorder Market, by Drug Class 
      2. Latin America Attention Deficit Hyperactivity Disorder Market, by Distribution Channel 
      3. Latin America Attention Deficit Hyperactivity Disorder Market, by Country/ Region
        1. Brazil
          1. Brazil Attention Deficit Hyperactivity Disorder Market, by Drug Class 
          2. Brazil Attention Deficit Hyperactivity Disorder Market, by Distribution Channel 
        2. Mexico
          1. Mexico Attention Deficit Hyperactivity Disorder Market, by Drug Class 
          2. Mexico Attention Deficit Hyperactivity Disorder Market, by Distribution Channel
        3. Argentina
          1. Argentina Attention Deficit Hyperactivity Disorder Market, by Drug Class 
          2. Argentina Attention Deficit Hyperactivity Disorder Market, by Distribution Channel 
        4. Rest of Latin America
          1. Rest of Latin America Attention Deficit Hyperactivity Disorder Market, by Drug Class 
          2. Rest of Latin America Attention Deficit Hyperactivity Disorder Market, by Distribution Channel
    5. Middle East & Africa Attention Deficit Hyperactivity Disorder Market
      1. Middle East & Africa Attention Deficit Hyperactivity Disorder Market, by Drug Class 
      2. Middle East & Africa Attention Deficit Hyperactivity Disorder Market, by Distribution Channel 
      3. Middle East & Africa a Attention Deficit Hyperactivity Disorder Market, by Country/ Region
        1. GCC Countries
          1. GCC Countries Attention Deficit Hyperactivity Disorder Market, by Drug Class 
          2. GCC Countries Attention Deficit Hyperactivity Disorder Market, by Distribution Channel 
        2. South Africa
          1. South Africa Attention Deficit Hyperactivity Disorder Market, by Drug Class 
          2. South Africa Attention Deficit Hyperactivity Disorder Market, by Distribution Channel
        3. Rest of Middle East & Africa
          1. Rest of Middle East & Africa Attention Deficit Hyperactivity Disorder Market, by Drug Class 
          2. Rest of Middle East & Africa Attention Deficit Hyperactivity Disorder Market, by Distribution Channel 
  8. COMPANY PROFILES         
    1. Pfizer, Inc.
      1. Business Snapshot 
      2. Products Offered
      3. Financial Details
      4. Strategic Development
    2. Johnson & Johnson Services, Inc.
    3. Lupin
    4. Novartis AG
    5. Takeda Pharmaceutical Company Limited
    6. Mallinckrodt plc.
    7. Purdue Pharma L.P.
    8. Neos Therapeutics, Inc.
    9. Supernus Pharmaceuticals, Inc.
    10. Eli Lilly and Company

*Insights on financial performance are subject to the availability of information in the public domain

List of Tables

 

  1. Global Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million)
  2. Global Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million) 
  3. Global Attention Deficit Hyperactivity Disorder Market, by Region, 2021-2031 (US$ Million) 
  4. North America Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  5. North America Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million) 
  6. North America Attention Deficit Hyperactivity Disorder Market, by Country, 2021-2031 (US$ Million) 
  7. U.S. Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  8. U.S. Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million) 
  9. Canada Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  10. Canada Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million) 
  11. Europe Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  12. Europe Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million) 
  13. Europe Attention Deficit Hyperactivity Disorder Market, by Country/ Region, 2021-2031 (US$ Million) 
  14. Germany Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  15. Germany Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million)
  16. U.K. Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  17. U.K. Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million
  18. France Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  19. France Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million) 
  20. Italy Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  21. Italy Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million) 
  22. Spain Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  23. Spain Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million) 
  24. Rest of Europe Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  25. Rest of Europe Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million) 
  26. Asia Pacific Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  27. Asia Pacific Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million) 
  28. Asia Pacific Attention Deficit Hyperactivity Disorder Market, by Country/ Region, 2021-2031 (US$ Million) 
  29. China Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  30. China Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million) 
  31. Japan Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  32. Japan Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million) 
  33. India Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  34. India Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million) 
  35. South Korea Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  36. South Korea Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million) 
  37. Australia Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  38. Australia Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million) 
  39. Rest of Asia Pacific Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  40. Rest of Asia Pacific Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million)
  41. Latin America Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  42. Latin America Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million) 
  43. Latin America Attention Deficit Hyperactivity Disorder Market, by Country/ Region, 2021–2031 (US$ Million)
  44. Brazil Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  45. Brazil Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million) 
  46. Mexico Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  47. Mexico Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million) 
  48. Argentina Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  49. Argentina Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million) 
  50. Rest of Latin America Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  51. Rest of Latin America Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million)
  52. Middle East and Africa Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  53. Middle East and Africa Attention Deficit Hyperactivity Disorder Market, by Distribution Channel 2021–2031 (US$ Million)
  54. Middle East and Africa Attention Deficit Hyperactivity Disorder Market, by Country/ Region, 2021–2031 (US$ Million)
  55. GCC Countries Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  56. GCC Countries Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million) 
  57. South Africa Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  58. South Africa Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million) 
  59. Rest of Middle East & Africa Attention Deficit Hyperactivity Disorder Market, by Drug Class, 2021-2031 (US$ Million) 
  60. Rest of Middle East & Africa Attention Deficit Hyperactivity Disorder Market, by Distribution Channel, 2021–2031 (US$ Million)

List of Figures

 

  1. Attention Deficit Hyperactivity Disorder Market Ecosystem  
  2. Snapshot of Global Attention Deficit Hyperactivity Disorder Market, 2021-2031 
  3. Snapshot of Global Attention Deficit Hyperactivity Disorder Market, by Region, 2021-2031
  4. Global Attention Deficit Hyperactivity Disorder Market: COVID-19 Pandemic Impact Assessment 
  5. Global Attention Deficit Hyperactivity Disorder Market: Key Players & Competitive Positioning (2021) 
  6. Attention Deficit Hyperactivity Disorder: Market Dynamics 
  7. Global Attention Deficit Hyperactivity Disorder for Stimulants, 2021-2031 (US$ Million) 
  8. Global Attention Deficit Hyperactivity Disorder Market for Amphetamine, 2021-2031 (US$ Million) 
  9. Global Attention Deficit Hyperactivity Disorder Market for Methylphenidate, 2021-2031 (US$ Million) 
  10. Global Attention Deficit Hyperactivity Disorder Market for Lisdexamfetamine 2021-2031 (US$ Million)
  11. Global Attention Deficit Hyperactivity Disorder Market for Dexmethylphenidate, 2021-2031 (US$ Million)
  12. Global Attention Deficit Hyperactivity Disorder Market for Dextroamphetamine, 2021-2031 (US$ Million) 
  13. Global Attention Deficit Hyperactivity Disorder Market for Non-stimulants, 2021-2031 (US$ Million) 
  14. Global Attention Deficit Hyperactivity Disorder Market for Atomoxetine, 2021-2031 (US$ Million) 
  15. Global Attention Deficit Hyperactivity Disorder Market for Others 2021-2031 (US$ Million) 
  16. Global Attention Deficit Hyperactivity Disorder Market for Clonidine, 2021-2031 (US$ Million) 
  17. Global Attention Deficit Hyperactivity Disorder Market for Hospital Pharmacies, 2021-2031 (US$ Million) 
  18. Global Attention Deficit Hyperactivity Disorder Market for Retail Pharmacies 2021-2031 (US$ Million) 
  19. Global Attention Deficit Hyperactivity Disorder Market for Online Pharmacies 2021-2031 (US$ Million)
  20. North America Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million) 
  21. U.S. Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million) 
  22. Canada Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million) 
  23. Europe Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million) 
  24. Germany Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million) 
  25. U.K. Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million) 
  26. France Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million) 
  27. Italy Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million) 
  28. Spain Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million) 
  29. Rest of Europe Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million) 
  30. Asia Pacific Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million) 
  31. China Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million) 
  32. Japan Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million) 
  33. India Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million) 
  34. South Korea Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million) 
  35. Australia Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million) 
  36. Rest of Asia Pacific Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million) 
  37. Latin America Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million) 
  38. Brazil Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million) 
  39. Mexico Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million) 
  40. Argentina Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million)
  41. Rest of Latin America Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million)
  42. Middle East & Africa Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million) 
  43. GCC Countries Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million) 
  44. South Africa Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million)
  45. Rest of Middle East & Africa Attention Deficit Hyperactivity Disorder Market, 2021-2031 (US$ Million)
  46. Pfizer, Inc. Revenue from 2019 Onwards (US$ Million)
  47. Johnson & Johnson Services, Inc. Revenue from 2019 Onwards (US$ Million)
  48. Lupin Limited Revenue from 2019 Onwards (US$ Million)
  49. Novartis AG Revenue from 2019 Onwards (US$ Million)
  50. Takeda Pharmaceutical Company Limited Revenue from 2019 Onwards (US$ Million)
  51. Mallinckrodt plc. Revenue from 2019 Onwards (US$ Million)
  52. Purdue Pharma L.P. Revenue from 2019 Onwards (US$ Million)
  53. Neos Therapeutics, Inc. Revenue from 2019 Onwards (US$ Million)
  54. Supernus Pharmaceuticals, Inc. Revenue from 2019 Onwards (US$ Million)
  55. Eli Lily and Company Revenue from 2019 Onwards (US$ Million)

Single User License
Single User License
Multi User License
Enterprise User License
$4,750.00
Provides access to one user only and should not be shared with other employees within the organization.
Provides access to up to five users within the department or an organization.
Provides access to all the employees in the organization. The report can also be shared with subsidiaries, sister concerns and group entities.
Grants user/users’ access to quantitative data only, which includes but is not restricted to numeric data, tables, and charts as defined by Growth+ Reports.
  • What are the significant driving and restraining factors for the Attention Deficit Hyperactivity Disorder Market?
  • Who are the leading companies in the market?
  • Where can you find the updates on recent developments by market players?
  • When is the right time to get discounts on complete market reports?
  • Why to invest in the Attention Deficit Hyperactivity Disorder Market?
  • How to improve your organizational performance?
  • How to shift customers towards your brand?

Recommended Reports